|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113059 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-24 15:54:02 |
|
注册时间: Date of Registration: |
2025-11-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于DNA损伤调控机制的牙髓炎活髓保存的诊断与治疗研究 |
|
Public title: |
Research on the Diagnosis and Treatment of pulp Preservation in pulpitis Based on DNA Damage Regulation Mechanism |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于DNA损伤调控机制的牙髓炎活髓保存的诊断与治疗研究 |
|
Scientific title: |
Research on the Diagnosis and Treatment of pulp Preservation in pulpitis Based on DNA Damage Regulation Mechanism |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李慧 |
研究负责人: |
江千舟 |
|
Applicant: |
Hui Li |
Study leader: |
Qianzhou Jiang |
|
申请注册联系人电话: Applicant telephone: |
+86 150 0468 8969 |
研究负责人电话:
Study leader's |
+86 20 8850 1865 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
595007218@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
958276432@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市荔湾区黄沙大道59号 |
研究负责人通讯地址: |
广东省广州市荔湾区黄沙大道59号 |
|
Applicant address: |
No. 59, Huangsha Avenue, Liwan District, Guangzhou City, Guangdong Province, China |
Study leader's address: |
No. 59, Huangsha Avenue, Liwan District, Guangzhou City, Guangdong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
202208080 | |
|
申请人所在单位: |
广州医科大学附属口腔医院 |
||
|
Applicant's institution: |
Affiliated Stomatological Hospital of Guangzhou Medical University |
||
|
研究负责人所在单位: |
广州医科大学附属口腔医院 |
||
|
Affiliation of the Leader: |
Affiliated Stomatological Hospital of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LCYJ20250228001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Affiliated Stomatological Hospital of Guangzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-03 00:00:00 | ||
|
伦理委员会联系人: |
余挺 |
||
|
Contact Name of the ethic committee: |
+86 20 8850 1865 |
||
|
伦理委员会联系地址: |
中国广东省广州市荔湾区黄沙大道59号 |
||
|
Contact Address of the ethic committee: |
No. 59, Huangsha Avenue, Liwan District, Guangzhou City, Guangdong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8850 1865 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Stomatological Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省广州市荔湾区黄沙大道59号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 59, Huangsha Avenue, Liwan District, Guangzhou City, Guangdong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州地区临床重大技术项目2026C-ZD042(牙髓炎活髓保存诊疗体系的建立与临床应用)、广州医科大学科研能力提升计划重大临床研究项目GMUCR2025-02024(不可复性牙髓炎活髓保存治疗的诊疗策略及预后评估研究)、广州市卫生健康科技一般引导项目20261A011094(恒牙牙髓炎伴龈下缺损的活髓保存治疗术后修复策略与预后相关性研究) |
||||||||||||||||||||||
|
Source(s) of funding: |
Major Clinical technical Project of Guangzhou Area 2026C-ZD042 (Establishment and Clinical Application of Pulp Preservation and Treatment System for Pulpitis), Major Clinical Research Project of Guangzhou Medical University's Scientific Research Capacity Enhancement Program GMUCR2025-02024 (Research on Diagnosis and Treatment Strategies and Prognosis Evaluation of Pulp Preservation and Treatment for Irreversible Pulpitis), Guangzhou Health Science and Technology I. General Guidance Project 20261A011094 (Study on the Correlation between Postoperative Repair Strategies and Prognosis of Pulp Preservation Treatment for Permanent Tooth pulpitis with Subgingival Defect) |
||||||||||||||||||||||
|
研究疾病: |
牙髓炎 |
||||||||||||||||||||||
|
Target disease: |
Pulpitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.明确适用于不可复性牙髓炎行VPT治疗预后判断的临床检测指标及意义。 2.揭示调控DNA损伤应答、调节牙髓炎发生发展的具体分子机制。 3.探究调控DNA损伤应答对VPT治疗不可复性牙髓炎预后的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.Clarify the clinical detection indicators and significance applicable to the prognosis judgment of VPT treatment for irreversible pulpitis. 2. Reveal the specific molecular mechanisms that regulate DNA damage responses and regulate the occurrence and development of pulpitis. 3. Explore the impact of regulating DNA damage response on the prognosis of irreversible pulpitis treated with VPT. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄在18至65岁之间; 2.恒磨牙出现临床和放射学证据表明深层龋病病变; 3.符合符合中华口腔医学会《临床诊疗指南:口腔医学分册》诊断标准; 4.患者同意参与研究且签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged between 18 and 65 years; 2. Permanent molars exhibiting clinical and radiographic evidence of deep caries lesions; 3. Meeting diagnostic criteria outlined in the Chinese Stomatological Association's Clinical Diagnosis and Treatment Guidelines: Oral Medicine Volume; 4. Patient consent to participate in the study and signed informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.有系统性疾病(如糖尿病、心血管疾病等)的患者; 2.过去一周内有服用止痛药或抗生素史的患者; 3.孕妇或哺乳期女性的患者; 4.患牙有外伤史、无法修复或无功能、存在牙周牙髓联合病变; 5.患牙X线显示根管钙化或牙根吸收迹象。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with systemic conditions (such as diabetes mellitus, cardiovascular disease, etc.); 2. Patients with a history of analgesic or antibiotic use within the past week; 3. Pregnant or breastfeeding patients; 4. Patients with a history of trauma to the affected tooth, where the tooth is irreparable or non-functional, or where combined periodontal and pulp pathology is present; 5. Patients where radiographs indicate root canal calcification or signs of root resorption in the affected tooth. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-03-03 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-24 00:00:00 至 To 2028-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机,医生应用应用随机数字表随机分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple randomization: Doctors are randomly assigned using a random number table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据需在2028年12月31日前以结构化格式(如?CSV、?Excel)提交,并确保去除受试者个人隐私信息。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data must be submitted in a structured format (such as ?CSV, ?Excel) by December 31, 2028, and ensure that the personal privacy information of the subjects is removed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集以病例记录表形式,数据上传到ResMan临床试验公共管理平台 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection was conducted in the form of case record forms, and the data was uploaded to the ResMan Clinical Trial Public Management Platform |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |